- Affimed N.V. (AFMD, Financial) receives Nasdaq deficiency notice for stock price under $1.00.
- The company has 180 days until October 13, 2025, to comply with listing requirements.
- Potential transfer to Nasdaq Capital Market could extend compliance period by 180 days.
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, has announced receiving a deficiency notice from Nasdaq, dated April 15, 2025, due to its stock price closing below the minimum requirement of $1.00 per share for the last 30 consecutive business days. The company now faces a significant challenge to meet the regulatory compliance standards mandated by Nasdaq.
In an attempt to address the deficiency, Affimed has been granted an initial 180-day compliance period expiring on October 13, 2025, during which it must ensure its stock price closes at or above the $1.00 threshold for a minimum of ten consecutive business days. If the company fails to achieve compliance within this timeframe, it may consider transferring its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.
This transfer, subject to meeting the applicable market value of publicly held shares and other listing criteria, could provide Affimed with an additional 180-day extension until April 13, 2026, to remedy the price deficiency. Despite receiving the notice, Affimed's shares will continue to be listed and traded normally during this period.
Affimed is exploring various strategies to address the issue, including business developments to naturally increase stock value and potential corporate actions such as a reverse stock split. The company's management remains focused on executing plans to regain compliance while continuing their commitment to advancing innovative cancer immunotherapy solutions.
